# Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer：MetBio-CRC

> **NCT07068529** · — · RECRUITING · sponsor: **Shanghai Minimally Invasive Surgery Center** · enrollment: 250 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07068529
- **Lead sponsor:** Shanghai Minimally Invasive Surgery Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07068529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07068529, "Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer：MetBio-CRC". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07068529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*